Full coverage: Israel

From the Government's bold move in 1999 to halt a Euro qualifier against Yugoslavia to today’s position to go ahead and play Israel, has Ireland traded moral leadership for a fixture behind closed doors?

The US military's decades-old footprint at the airport continues to fuel a high-stakes clash between soft-power pragmatism and the idea that Ireland remains a neutral country in any legal sense of the word.

As a new wave of activists target US military assets at the Midwest airport, The Currency looks back at 25 years of protest, successive governments’ relationship with the US, and the debate over Ireland’s role in the transatlantic alliance.

Lawmakers are hiring AI advisers, working to influence chatbot results and churning out AI-generated ads faster than regulators can keep up, writes Anat Peled, The Wall Street Journal.

State files show multiple licences were granted for export during the height of the assault on Gaza and Lebanon, followed by a swift shift to restrict exports in late 2024 after stricter EU laws came into effect.

As security forces lock down Druids Glen from the Red Scare, the EU’s toothless diplomacy on Israel leaves us exposed to the real consequences of unchecked aggression.

Next month, the Central Bank must make a decision that will determine if Israel can market bonds to EU investors. It says it is bound by strict EU rules as activists, legal experts, and the finance committee call for refusal in line with international law. What comes next?

Released files show the Corporate Enforcement Authority has a contract with Cellebrite, a digital intelligence company with deep links to Israeli intelligence and whose products have been used by repressive regimes and to crack the phone of a reporter in Northern Ireland.

Foreign affairs and trade minister Helen McEntee faced questions from MEPs this week about the EU’s controversial trading partners, setting up challenging sets of talks ahead.

The Galway company’s attempts to raise a $50m Series C round fell through and a liquidator has been called in just weeks after it published the results of its latest clinical trial.